3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Prostatic Neoplasms
112
Lymphoma
66
Lymphoma, Large B-Cell, Diffuse
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Non-Hodgkin
29
Lymphoma, Follicular
22
Burkitt Lymphoma
22
Multiple Myeloma
19
Leukemia
16
Hodgkin Disease
16
Neoplasms
14
Neoplasm Metastasis
13
Lymphoma, B-Cell
13
Lymphoma, Mantle-Cell
11
Lymphoma, Large-Cell, Anaplastic
11
Lymphoma, T-Cell
8
Lymphoma, B-Cell, Marginal Zone
8
Lymphoma, T-Cell, Peripheral
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Hematologic Neoplasms
5
Waldenstrom Macroglobulinemia
4
Recurrence
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, AIDS-Related
4
Immunoblastic Lymphadenopathy
4
Prostate Cancer Metastatic
3
Primary Myelofibrosis
3
Polycythemia Vera
3
Plasmablastic Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
cemiplimab
2
Sirolimus
1
Prednisone
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Cutaneous Squamous Cell Carcinoma
×
Prednisone
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts